drugset / Trial / NCT06124378
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study aims to elucidate the effects of neoadjuvant Tislelizumab combined with chemotherapy in locally advanced Microsatellite Stable (MSS) colon cancer.
Timeline
- Start
- 2023-11-13
- Primary completion
- 2025-02-28
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |